Kupando GmbH
Angelika Leppert is an accomplished financial executive with extensive experience in the biopharmaceutical and consulting sectors. Currently serving as Chief Financial Officer at KUPANDO GmbH since May 2020, Angelika leads financial strategies for a company focused on developing novel TLR 4/7 agonist therapies. Previous roles include Start-up Coach at BioM Biotech Cluster Development GmbH, where Angelika designed funding concepts and facilitated strategic workshops, and Management Consultant & Business Coach in a self-employed capacity, offering corporate finance and organizational development services. Angelika held leadership positions at Medigene AG, overseeing corporate finance and HR functions, and worked as a Senior Consultant at Roland Berger. Angelika's educational background includes a Diplom Kauffrau in Business Economics from the University of Regensburg and various specialized certifications in business coaching and corporate finance.
This person is not in any teams
This person is not in any offices
Kupando GmbH
Kupando is a pioneering biopharmaceutical company developing TLR 4/7 agonists that stimulate innate immunity for use in oncology and infectious diseases. The Company uses its small molecule-based drug candidates to build a pipeline in several indications, in-house or via strategic partnerships, as single agent, or in combination with checkpoint inhibitors, other drugs or antigens. Its drug candidate KUP101 is the only TLR 4/7 agonist in development and consists of two small molecules, TLR4 agonist and TLR7 agonist, co-encapsulated. IND-enabling work is on-going for treatment of solid tumors and prophylaxis of infectious diseases. Kupando is a private company, seed financed by its CEO Johanna Holldack and based on technology invented by Dennis Carson’s Laboratory at the University of California San Diego. The Company’s management team brings a unique wealth of experience in business and drug development, gained in the US and Europe. Kupando is headquartered in Schoenefeld, Germany.